0
Poster Presentations: Wednesday, October 26, 2011 |

Fatigue in Pulmonary Arterial Hypertension: Defining and Measuring a Key Symptom for Instrument Development FREE TO VIEW

Matthew Murawski, PhD; Robert Frantz, MD; Mardi Gomberg-Maitland, MD; Hubert Chen, MD; Joel Fain, PhD; James Cwengros, PharmD; Kafi Sanders, MPH
Chest. 2011;140(4_MeetingAbstracts):710A. doi:10.1378/chest.1119902
Text Size: A A A
Published online

Abstract

PURPOSE: To review the nature and multi-dimensional aspects of fatigue in several different disease states and to develop a preliminary conceptualization of the nature of fatigue in PAH. To suggest aspects of fatigue that should be evaluated in PAH patients.

METHODS: Broad systematic review of the PAH literature. Search terms used were “PAH”, “quality of life”, and “patient reported outcomes”, and “fatigue”. Results were synthesized and consistent trends identified. The PAH literature is reviewed in order to develop a working conceptual model of the dimensions of fatigue previously noted in PAH

RESULTS: Fatigue is a key patient symptom in PAH, a potential marker for disease progression and may be predictive of patient deterioration. Review of the literature surrounding fatigue in other disease states, notably undifferentiated cancer, breast cancer, chronic fatigue syndrome, and HIV make clear that fatigue in each of these disease states is a multi-dimensional construct. General fatigue has been shown to be distinguishable between fatigue associated with direct physical limitations such as oxygenation/perfusion due to cardiac inefficiency, fatigue resulting as a consequence of insomnia or of challenges of sleep loss, fatigue associated with the symptoms of depression or as a consequence of anxiety, and fatigue arising as a consequence of the burdens imposed by therapy or insufficient rest due to medications.

CONCLUSIONS: Fatigue in PAH is a multi-dimensional construct, involving fatigue arising as a consequence of inadequate cardiac efficiency, inadequate or un-restful sleep, and as a consequence of anxiety or depression.

CLINICAL IMPLICATIONS: Development of a conceptual model of fatigue in PAH and its impact on patients is a first, necessary step in the systematic quantification of fatigue in this population. Understanding the different forms and causes of patient fatigue will enhance the clinician’s understanding of the impact of the disease and treatment on the PAH patient’s quality of life.

DISCLOSURE: Matthew Murawski: Consultant fee, speaker bureau, advisory committee, etc.: Mattthew Murawski serves as a consultant to Pfizer,Inc

Robert Frantz: Grant monies (from industry related sources): Pfizer: Consulting fees,United Therapeutics: Served on advisory boards without personal financial gain. but with coverage of travel expense. Received research support. Received educational grants., Consultant fee, speaker bureau, advisory committee, etc.: Actelion: Served on advisory boards without personal financial gain but with coverage of travel expense.. Received educational grants.Gilead: Served on advisory boards without personal financial gain, but with coverage of travel expense., Other: Bayer: Consulting to develop educational program with them; my institution received the fees in keeping with Mayo COI policy for investigators.

Mardi Gomberg-Maitland: Grant monies (from industry related sources): Actelion, Gilead, Lilly/Icos, Pfizer, Novartis, and United Therapeutics have provided funding to the University of Chicago to support Dr. Gomberg-Maitland’s conduct of clinical trials., Consultant fee, speaker bureau, advisory committee, etc.: She has served as a consultant/participant on data safety monitoring board/steering committee for clinical trials for Actelion, Drais, Gilead, Medtronic, and Pfizer.

Hubert Chen: Grant monies (from industry related sources): Pfizer,Inc, Consultant fee, speaker bureau, advisory committee, etc.: United Therapeutics, Consultant fee, speaker bureau, advisory committee, etc.: Genentech

Joel Fain: Employee: Pfizer,Inc

James Cwengros: Employee: Pfizer,Inc

Kafi Sanders: Employee: Pfizer,Inc

No Product/Research Disclosure Information

09:00 AM - 10:00 AM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543